RT @aSciStance@twitter.com

I have translated clinical trial and regulatory documents for so many of those medicines! Good to see that they are discussed by #CHMP
#FeelingUseful https://twitter.com/EMA_News/status/1617483638635114496

🐦🔗: https://twitter.com/aSciStance/status/1617500844047450113

RT @EMA_News@twitter.com

The #CHMP recommended for authorisation the 1⃣st gene therapy to treat #haemophilia B in adults ⬇️

https://www.ema.europa.eu/en/news/first-gene-therapy-treat-haemophilia-b

🐦🔗: https://twitter.com/EMA_News/status/1603711318233649152

RT @U12Schutz
Die Tagesordnung für das #chmp Meeting der @EMA_News ist veröffentlicht. Neben neuen Medikamenten geht es auch wieder um Impfstoffe. https://twitter.com/EMA_News/status/1589573047736225792

RT @BioNTech_Group@twitter.com

A booster dose of our Omicron BA.4/BA.5-adapted bivalent #COVID19 vaccine developed with @Pfizer@twitter.com has been recommended for marketing authorization by the @EMA_News@twitter.com’ #CHMP for children 5-11. https://investors.biontech.de/news-releases/news-release-details/pfizer-and-biontech-receive-positive-chmp-opinion-omicron-0

🐦🔗: https://twitter.com/BioNTech_Group/status/1590718161183047686

Schön, dass es dieses Mal schneller geht, auch für die Kids! 👍🏻

RT @BioNTech_Group@twitter.com

A booster dose of our Omicron BA.4/BA.5-adapted bivalent #COVID19 vaccine developed with @Pfizer@twitter.com has been recommended for marketing authorization by the @EMA_News@twitter.com’ #CHMP for children 5-11. https://investors.biontech.de/news-releases/news-release-details/pfizer-and-biontech-receive-positive-chmp-opinion-omicron-0

🐦🔗: https://twitter.com/BioNTech_Group/status/1590718161183047686

RT @BioNTech_Group@twitter.com

A booster dose of our Omicron BA.4/BA.5-adapted bivalent #COVID19 vaccine developed with @Pfizer@twitter.com has been recommended for marketing authorization by the @EMA_News@twitter.com’ #CHMP for children 5-11. https://investors.biontech.de/news-releases/news-release-details/pfizer-and-biontech-receive-positive-chmp-opinion-omicron-0

🐦🔗: https://twitter.com/BioNTech_Group/status/1590718161183047686

RT @BioNTech_Group
A booster dose of our Omicron BA.4/BA.5-adapted bivalent #COVID19 vaccine developed with @pfizer has been recommended for marketing authorization by the @EMA_News’ #CHMP for children 5-11. https://investors.biontech.de/news-releases/news-release-details/pfizer-and-biontech-receive-positive-chmp-opinion-omicron-0

Die Tagesordnung für das #chmp Meeting der EMA_News ist veröffentlicht. Neben neuen Medikamenten geht es auch wieder um Impfstoffe.
Quelle: https://t.co/6b6jdn4VC8
Für uns relevant werden:
BioNTech: Erweiterung der Zulassung /Seite 14/15
Der erste Punkt bezieht sich auf den bivalenten Impfstoff für die Altersgruppe 5-12.
Der zweite Punkt ist der Nachtrag zur U5 Zulassung vor einigen Wochen.